Quibron T is a prescription medication specifically formulated to manage and prevent symptoms associated with reversible bronchospasm in conditions such as asthma, chronic bronchitis, and emphysema. It combines the bronchodilating effects of theophylline with guaifenesin, an expectorant, to facilitate easier breathing and improved mucus clearance. This dual-action approach targets both airway constriction and mucus accumulation, providing comprehensive respiratory support for patients with obstructive airway diseases. Clinical use is guided by therapeutic drug monitoring to optimize efficacy and minimize risks, making it a cornerstone in long-term respiratory management under professional supervision.

Features

• Contains theophylline anhydrous 300 mg and guaifenesin 100 mg per tablet
• Extended-release formulation for sustained bronchodilation over 12 hours
• Promotes bronchial smooth muscle relaxation and mucolytic action
• Designed for twice-daily dosing to support adherence
• Requires therapeutic drug monitoring for individualized dosing

Benefits

• Provides prolonged relief from bronchospasm and wheezing
• Enhances mucus expulsion from the airways, reducing congestion
• Supports improved exercise tolerance and daily activity performance
• Helps decrease the frequency and severity of asthma attacks
• Contributes to long-term control of chronic obstructive pulmonary disease (COPD) symptoms
• Facilitates better sleep quality by reducing nighttime respiratory symptoms

Common use

Quibron T is indicated for the symptomatic treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, emphysema, and other chronic obstructive pulmonary diseases. It is particularly useful in patients who require sustained bronchodilation and expectant therapy to manage persistent cough and airway obstruction. The medication is often incorporated into a broader management plan that may include inhaled corticosteroids, lifestyle modifications, and avoidance of triggers.

Dosage and direction

Dosage must be individualized based on patient factors such as age, weight, smoking status, and concomitant illnesses, and should be guided by serum theophylline levels. The usual adult dose is one tablet every 12 hours, though some patients may require adjustment to one tablet every 8 hours. Tablets should be swallowed whole and not crushed or chewed, and may be taken with or without food—though consistency in administration with respect to meals is advised. Dosage titration should proceed cautiously, especially in patients with hepatic impairment, congestive heart failure, or those taking medications that affect theophylline metabolism.

Precautions

Use with caution in patients with a history of peptic ulcer disease, gastroesophageal reflux, seizures, cardiac arrhythmias, hypertension, or hyperthyroidism. Elderly patients and those with liver dysfunction, heart failure, or prolonged fever may have reduced theophylline clearance and require lower doses. Avoid use in individuals with hypersensitivity to any component. Patients should be advised to limit caffeine intake, as it may exacerbate side effects. Regular monitoring of serum theophylline concentrations is essential to maintain levels within the therapeutic range (10–20 mcg/mL).

Contraindications

Quibron T is contraindicated in patients with known hypersensitivity to theophylline, guaifenesin, or any component of the formulation. It should not be used in those with active peptic ulcer disease or uncontrolled seizure disorders. Concurrent use with other xanthine derivatives is not recommended. The product is also contraindicated in individuals with porphyria.

Possible side effect

Common side effects may include nausea, vomiting, headache, insomnia, restlessness, and gastric irritation. Less frequently, patients may experience palpitations, tachycardia, hypotension, hyperglycemia, or diuresis. Serious adverse effects such as seizures or life-threatening arrhythmias are rare but may occur, especially with elevated serum theophylline levels. Any persistent or severe symptoms should be reported to a healthcare provider immediately.

Drug interaction

Quibron T interacts with numerous medications. CYP1A2 inhibitors (e.g., cimetidine, fluvoxamine, erythromycin) can increase theophylline levels, while inducers (e.g., phenytoin, rifampin, smoking) can decrease them. Concurrent use with other sympathomimetics may increase the risk of cardiovascular effects. Beta-blockers may antagonize bronchodilator effects. Caution is advised with quinolone antibiotics, allopurinol, and oral contraceptives. A thorough medication review is essential before initiation.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next dose. In that case, skip the missed dose and resume the regular schedule. Do not double the dose to catch up.

Overdose

Theophylline overdose can be serious and potentially fatal. Symptoms may include severe nausea, vomiting, tachycardia, hypotension, agitation, seizures, and cardiac arrest. Management involves discontinuation of the drug, supportive care, and possibly activated charcoal or extracorporeal removal in severe cases. Serum theophylline levels should be monitored, and medical attention sought immediately.

Storage

Store at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual patient needs and circumstances must be evaluated by a medical professional.

Reviews

Clinical studies and patient reports indicate that Quibron T is effective in managing bronchospastic symptoms and improving quality of life when used appropriately under medical supervision. Many users note significant improvement in breathing capacity and reduction in exacerbation frequency. However, the necessity for careful dosing and monitoring is frequently emphasized in expert reviews to mitigate the risk of side effects and interactions.